ORKA-001 Delivers High Rate of Skin Clearance at Week 16, Suggests Potential for Once-Yearly Psoriasis Treatment

Strong Efficacy: Over 60% of Patients Achieve Full Clearance

Oruka Therapeutics' investigational drug ORKA-001 reached a notable milestone in the ongoing EVERLAST-A Phase 2a trial for moderate-to-severe plaque psoriasis. At Week 16, 40 out of 63 participants (63.5%) who received ORKA-001 achieved complete skin clearance, as measured by the PASI 100 endpoint. This result is at the upper end of what is typically observed across all categories of psoriasis treatments, including other IL-23p19 inhibitors.

The response was consistent with the IGA 0 endpoint, and high levels were also seen in key secondary measures: PASI 90 was reached by 83% and IGA 0/1 by 84% of the treated participants. In the placebo group, just one out of 21 patients achieved these outcomes.

Safety Profile: Similar to Placebo with Mild Adverse Events

Safety remains a strong aspect for ORKA-001. The rate of treatment-emergent adverse events (TEAEs) was 51% in the ORKA-001 arm and 57% in the placebo group. Most TEAEs were mild across both arms, with no serious TEAEs in those receiving ORKA-001 and only one severe event in the placebo group. The only side effect reported in at least 5% of any group was upper respiratory tract infection—19% for ORKA-001 and 14% for placebo. Notably, there were no injection site reactions observed so far.

Pharmacokinetics Point to Once-Yearly Dosing as a Realistic Goal

Updated pharmacokinetic (PK) and pharmacodynamic (PD) analysis from an earlier Phase 1 study continues to support the concept of annual dosing. After a single 600 mg dose, ORKA-001 stayed above the necessary threshold for effective IL-23 inhibition for an entire year. No anti-drug antibodies affecting drug levels were observed in either Phase 1 or the current trial. If this long-acting potential holds up in subsequent studies, it could significantly reduce the treatment burden for patients, representing a genuine advance over currently available biologics.

Upcoming Milestones: Data at Week 28 and 52 Expected in 2H 2026

Oruka Therapeutics plans to share longer-term data, including 28-week efficacy for all participants and 52-week follow-up for a subset, in the second half of 2026. There is also an ongoing Phase 2b study (EVERLAST-B), with readouts planned for 2027, which will help determine if these phase 2a results translate into a durable clinical benefit over extended periods.

Takeaway: ORKA-001 May Set a New Standard for Psoriasis Care

The high rate of complete skin clearance, benign safety profile, and strong potential for annual dosing place ORKA-001 in a compelling position among psoriasis biologics in development. Should these trends persist in larger and longer studies, the drug could offer patients not only superior efficacy but unmatched convenience. Investors and stakeholders will want to watch for the upcoming 28- and 52-week data for validation—and potentially, a glimpse at future standard-of-care for moderate-to-severe plaque psoriasis.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI